The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Marketwire

ProMetic to Hold Second Quarter 2011 Financial Results Conference Call and Webcast

Wednesday, August 10, 2011

ProMetic to Hold Second Quarter 2011 Financial Results Conference Call and Webcast07:30 EDT Wednesday, August 10, 2011MONTREAL, QUEBEC, CANADA--(Marketwire - Aug. 10, 2011) - ProMetic Life Sciences Inc. (TSX:PLI)("ProMetic" or the "Company") today announced that it will report its financial results for the second quarter of 2011 on Monday, August 15, 2011 before market opening.ProMetic will host a conference call at 10:30am (EST) on Monday, August 15, 2011. The telephone numbers to access the conference call are (416) 981-9000 (International) and 1-888-754-4437 (Toll-free). A live audio webcast of the conference call will be available through ProMetic's website at http://www.prometic.com/en/investors/presentations-webcasts.phpAn audio replay of the call will be available for a period of seven days as of Monday, August 15, 2011, at 12:30 (EST). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America toll free) using access code 21534878. The replay of the webcast may be downloaded directly from ProMetic's web site.About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.Forward Looking Statements This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic's Annual Information Form for the year ended December 31, 2009, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.FOR FURTHER INFORMATION PLEASE CONTACT: President and CEOPierre LaurinProMetic Life Sciences Inc.p.laurin@prometic.com+1.450.781.0115ORDirector, Communications andFrederic DumaisInvestor RelationsProMetic Life Sciencesf.dumais@prometic.com+1.450.781.0115